GBM AGILE: Fighting Deadly Cancers

GBM AGILE: Changing the way we fight cancer!

GBM AGILE is a revolutionary clinical trial platform designed for patients battling the deadliest brain cancer, glioblastoma. The AGILE trial design is a model for drug development to support patients with other rare cancers and diseases.

Clinical and scientific leadership for GBM recognized the need to advance effective treatments for patients with this incurable and universally fatal cancer. They joined forces to create an innovative clinical trial platform to accelerate the evaluation of new treatments for GBM. By efficiently testing multiple drugs and drug combinations simultaneously, GBM AGILE serves as a patient-centered initiative to improve treatment options for patients.

As a founding member of GBM AGILE, NFCR has taken a leading role in this unprecedented global effort. With help from our generous supporters, rapid progress is being made–new trial sites are opening in the US and around the world, patients are being enrolled and receiving the most promising treatments. Your support is crucial—together we can conquer the most challenging cancers and diseases.

Support Cancer Research Today

Learn More About Enrollment

History in the Making

Since its inception, GBM AGILE continues to advance treatments for brain cancer in ways never before imagined.

Learn More

Our Impact

Since Day 1, NFCR has partnered with donors and other charities to bring new treatments to brain cancer patients through GBM AGILE.

Learn More

Resources for Patients

GBM AGILE’s revolutionary approach has provided new hope to patients. Find enrollment information and other resources here.

Learn More

A Hero’s Last Battle

Before losing his battle with brain cancer, former U.S Marine officer Dwayne Osgood, sent an inspiring message to the cancer community. Through participation in NFCR’s Play4TheCure program, Dwayne and his teammates raised over $38,000 to support GBM AGILE. Throughout his journey with cancer, Dwayne continued to remain positive and turned his unexpected challenge into a remarkable opportunity to make a significant impact on cancer research.